Transdermal estradiol with micronized progesterone is the preferred form of menopause hormone therapy.
32 sources: 17 positive, 10 partly, 5 negative.
Researchers say
5 partly
-
Dr. Mary Claire Haver, 2 mentions on this claim
Partly Video
-
on Huberman Lab, at 1:21:26 · partly
“for that reason I tend to go with the non-oral formulations to avoid that risk”
-
on The Diary Of A CEO, at 52:41 · partly
“if they avoid oral estrogen and go with a non-oral form like the patch or the ring or or even a pellet”
-
-
Dr. Peter Attia, on FoundMyFitness, at 2:53:06
Partly Video · Opinion
Open the tape at 2:53:06 →“our Preferred Product is an estradiol patch”
-
Dr Sharon Malone, on The Dr. Hyman Show, at 1:02:00
Partly Video · Opinion
Open the tape at 1:02:00 →“um that a a transermal may be preferable”
-
Cynthia Guyer, on The Dr. Hyman Show, at 18:29
Partly Video · Opinion
Open the tape at 18:29 →“So I tend to use the transdermal because I think it's better tolerated”
-
Gayatri Devi, on The Drive, at 1:49:43
Partly Video · Opinion
Open the tape at 1:49:43 →“I actually prefer transermal in a you know either a gel or a patch”
Studies show
17 positive, 5 partly, 5 negative
27 papers we read
-
Trial or observed group, Lancet, 2003, PMID 12927428
Positive Study
Read the paper on PubMed →Estimated risk for VTE in current users of oral ERT compared with transdermal ERT users was 4.0 (1.9-8.3).
-
Trial or observed group, Circulation, 2005, PMID 16301339
Positive Study
Read the paper on PubMed →Oral but not transdermal estrogen was associated with an increased risk of VTE (odds ratio [OR], 4.3; 95% CI, 2.6 to 7.2; and OR, 1.2; 95% CI, 0.8 to 1.7, respectively).
-
Trial or observed group, J Thromb Haemost, 2006, PMID 16706969
Positive Study
Read the paper on PubMed →Oral, not transdermal, estrogen was associated with an increased VTE risk (OR = 4.5; 95% CI: 2.6-7.7 and OR = 1.1; 95% CI: 0.7-1.7, respectively).
-
Pooled analysis, BMJ, 2008, PMID 18495631
Positive Study
Read the paper on PubMed →Meta-analysis of observational studies showed that oral oestrogen but not transdermal oestrogen increased the risk of venous thromboembolism.
-
Other primary study, J Thromb Haemost, 2010, PMID 20230416
Positive Study
Read the paper on PubMed →The risk of VTE was not increased with current use of transdermal estrogen alone (RR 1.01; 95% CI, 0.89-1.16) or combined with a progestogen (RR 0.96; 95% CI, 0.77-1.20), or with current use of tibolone (RR 0.92; 95% CI: 0.77-1.10), relative to non-use.
-
Other primary study, Menopause, 2011, PMID 21178641
Positive Study
Read the paper on PubMed →Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women.
-
Other primary study, Menopause, 2011, PMID 21775912
Positive Study
Read the paper on PubMed →After adjustment for confounding factors, the incidence of venous thromboembolism remained significantly lower for estradiol transdermal system users than for estrogen-only hormone therapy users.
-
Other primary study, J Thromb Haemost, 2012, PMID 22963114
Positive Study
Read the paper on PubMed →RRs in current vs. never users at last reporting varied by HT formulation: the risk was significantly greater for oral estrogen-progestin than oral estrogen-only therapy (RR = 2.07 [95%CI, 1.86-2.31] vs. 1.42 [1.21-1.66]), with no increased risk with transdermal estrogen-only therapy (0.82 [0.64-1.06]).
-
Trial or observed group, J Thromb Haemost, 2013, PMID 23136837
Positive Study
Read the paper on PubMed →Non-oral HT did not increase the risk of VT: OR 1.1 (0.6-1.8).
-
Other primary study, Menopause, 2016, PMID 27023862
Positive Study
Read the paper on PubMed →Transdermal estrogen combined with progestogen was not associated with VTE risk (crude and imprecise ORs ranging from 0.87 to 1.16).
-
Other primary study, Stroke, 2017, PMID 28626058
Positive Study
Read the paper on PubMed →We found no risk of stroke with transdermal application and a reduced risk with vaginal estrogen.
-
Trial or observed group, BMJ, 2019, PMID 30626577
Positive Study
Read the paper on PubMed →Transdermal preparations were not associated with risk of venous thromboembolism, which was consistent for different regimens (overall adjusted odds ratio 0.93, 95% confidence interval 0.87 to 1.01).
-
Pooled analysis, Sci Rep, 2020, PMID 33244065
Positive Study
Read the paper on PubMed →Routes of administration Oral 9 1.41 (1.19–1.67) 72.5 < 0.01 Non-oral 7 0.81 (0.60–1.09) 70.8 < 0.01
-
Systematic review, Arch Gynecol Obstet, 2023, PMID 35713694
Positive Study
Read the paper on PubMed →VTE risk can be considered the clearest and strongest clinical difference between the two administration routes, supporting the transdermal HRT as safer than the oral administration route.
-
Other primary study, Climacteric, 2022, PMID 36218141
Positive Study
Read the paper on PubMed →The risk of PE was significantly increased in users of oral but not transdermal MHT, with the highest risk in first ever users of oral estrogen combined with medroxyprogesterone acetate.
-
Other primary study, Res Pract Thromb Haemost, 2023, PMID 37193125
Positive Study
Read the paper on PubMed →For exposures within 60 days, oral MHT risk was almost twice as high as transdermal MHT (OR = 1.92; 95% CI, 1.43-2.60); transdermal MHT did not elevate risk compared with no exposure (unopposed OR = 0.70; 95% CI, 0.59-0.83; combined OR = 0.73; 95% CI, 0.56-0.96).
-
Other primary study, BMJ, 2026, PMID 42778212
Positive Study
Read the paper on PubMed →No increased thrombotic risks were observed with transdermal therapy.
-
Other primary study, Int J Cancer, 2005, PMID 15551359
Partly Study
Read the paper on PubMed →The risk was significantly greater (p <0.001) with HRT containing synthetic progestins than with HRT containing micronized progesterone, the RRs being 1.4 [1.2-1.7] and 0.9 [0.7-1.2], respectively.
-
Trial or observed group, Circulation, 2007, PMID 17309934
Partly Study
Read the paper on PubMed →In addition, our data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect to thrombotic risk.
-
Other primary study, Breast Cancer Res Treat, 2008, PMID 17333341
Partly Study
Read the paper on PubMed →This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous).
-
Trial or observed group, BMJ, 2010, PMID 20525678
Partly Study
Read the paper on PubMed →The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)).
-
Trial or observed group, Menopause, 2014, PMID 24045672
Partly Study
Read the paper on PubMed →In direct comparisons, various HT doses and regimens are associated with similar rates of cardiovascular events and all-cause mortality.
-
Other primary study, Maturitas, 2006, PMID 16040209
Negative Study
Read the paper on PubMed →No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p>0.44).
-
Trial or observed group, Am J Epidemiol, 2014, PMID 25008104
Negative Study
Read the paper on PubMed →In conclusion, micronized progesterone and, to a lesser extent, dydrogesterone at the doses used in France may not be sufficient to prevent estrogen-induced endometrial cancers.
-
Other primary study, Menopause, 2021, PMID 34313612
Negative Study
Read the paper on PubMed →Among women veterans, the risk of VTE was similar in users of oral CEE, oral E2, and transdermal E2.
-
Other primary study, BJOG, 2024, PMID 38465460
Negative Study
Read the paper on PubMed →After adjusting for confounding factors, an increased risk of CVD was observed with the administration of tibolone (hazard ratio, HR 1.143, 95% CI 1.117-1.170), oral estrogen (HR 1.246, 95% CI 1.198-1.295) or transdermal estrogen (HR 1.289, 95% CI 1.066-1.558), compared with the non-MHT group; the risk was based on an increased risk of stroke.
-
Other primary study, BMJ, 1997, PMID 9081000
Negative Study
Read the paper on PubMed →No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations.
16 more not counted · see why
The study is not yet read in full. 6
- Pooled analysis, Curr Opin Hematol, 2010, PMID 20601871
- Pooled analysis, J Clin Endocrinol Metab, 2015, PMID 26544651
- Pooled analysis, Thromb Res, 2018, PMID 29936403
- Systematic review, Hum Reprod Update, 2019, PMID 30508190
- Systematic review, Climacteric, 2022, PMID 35112635
- Systematic review, Climacteric, 2025, PMID 40488293
We could not tell where the evidence comes from. 3
We could not confirm who is speaking. 3
The study cited could not be identified. 2
A host's remark inside an interview. 1
We could not tell what position it takes on this claim. 1
Show the receipts from 32 sources
-
Trial or observed group, Lancet, 2003, PMID 12927428 Study · positive
Estimated risk for VTE in current users of oral ERT compared with transdermal ERT users was 4.0 (1.9-8.3).
-
Trial or observed group, Circulation, 2005, PMID 16301339 Study · positive
Oral but not transdermal estrogen was associated with an increased risk of VTE (odds ratio [OR], 4.3; 95% CI, 2.6 to 7.2; and OR, 1.2; 95% CI, 0.8 to 1.7, respectively).
-
Trial or observed group, J Thromb Haemost, 2006, PMID 16706969 Study · positive
Oral, not transdermal, estrogen was associated with an increased VTE risk (OR = 4.5; 95% CI: 2.6-7.7 and OR = 1.1; 95% CI: 0.7-1.7, respectively).
-
Pooled analysis, BMJ, 2008, PMID 18495631 Study · positive
Meta-analysis of observational studies showed that oral oestrogen but not transdermal oestrogen increased the risk of venous thromboembolism.
-
Other primary study, J Thromb Haemost, 2010, PMID 20230416 Study · positive
The risk of VTE was not increased with current use of transdermal estrogen alone (RR 1.01; 95% CI, 0.89-1.16) or combined with a progestogen (RR 0.96; 95% CI, 0.77-1.20), or with current use of tibolone (RR 0.92; 95% CI: 0.77-1.10), relative to non-use.
-
Other primary study, Menopause, 2011, PMID 21178641 Study · positive
Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women.
-
Other primary study, Menopause, 2011, PMID 21775912 Study · positive
After adjustment for confounding factors, the incidence of venous thromboembolism remained significantly lower for estradiol transdermal system users than for estrogen-only hormone therapy users.
-
Other primary study, J Thromb Haemost, 2012, PMID 22963114 Study · positive
RRs in current vs. never users at last reporting varied by HT formulation: the risk was significantly greater for oral estrogen-progestin than oral estrogen-only therapy (RR = 2.07 [95%CI, 1.86-2.31] vs. 1.42 [1.21-1.66]), with no increased risk with transdermal estrogen-only therapy (0.82 [0.64-1.06]).
-
Trial or observed group, J Thromb Haemost, 2013, PMID 23136837 Study · positive
Non-oral HT did not increase the risk of VT: OR 1.1 (0.6-1.8).
-
Other primary study, Menopause, 2016, PMID 27023862 Study · positive
Transdermal estrogen combined with progestogen was not associated with VTE risk (crude and imprecise ORs ranging from 0.87 to 1.16).
-
Other primary study, Stroke, 2017, PMID 28626058 Study · positive
We found no risk of stroke with transdermal application and a reduced risk with vaginal estrogen.
-
Trial or observed group, BMJ, 2019, PMID 30626577 Study · positive
Transdermal preparations were not associated with risk of venous thromboembolism, which was consistent for different regimens (overall adjusted odds ratio 0.93, 95% confidence interval 0.87 to 1.01).
-
Pooled analysis, Sci Rep, 2020, PMID 33244065 Study · positive
Routes of administration Oral 9 1.41 (1.19–1.67) 72.5 < 0.01 Non-oral 7 0.81 (0.60–1.09) 70.8 < 0.01
-
Systematic review, Arch Gynecol Obstet, 2023, PMID 35713694 Study · positive
VTE risk can be considered the clearest and strongest clinical difference between the two administration routes, supporting the transdermal HRT as safer than the oral administration route.
-
Other primary study, Climacteric, 2022, PMID 36218141 Study · positive
The risk of PE was significantly increased in users of oral but not transdermal MHT, with the highest risk in first ever users of oral estrogen combined with medroxyprogesterone acetate.
-
Other primary study, Res Pract Thromb Haemost, 2023, PMID 37193125 Study · positive
For exposures within 60 days, oral MHT risk was almost twice as high as transdermal MHT (OR = 1.92; 95% CI, 1.43-2.60); transdermal MHT did not elevate risk compared with no exposure (unopposed OR = 0.70; 95% CI, 0.59-0.83; combined OR = 0.73; 95% CI, 0.56-0.96).
-
Other primary study, BMJ, 2026, PMID 42778212 Study · positive
No increased thrombotic risks were observed with transdermal therapy.
-
Dr. Mary Claire Haver Video · partly · 2 mentions
on Huberman Lab, at 1:21:26 · partly · Opinion
“for that reason I tend to go with the non-oral formulations to avoid that risk”
on The Diary Of A CEO, at 52:41 · partly · Opinion
“if they avoid oral estrogen and go with a non-oral form like the patch or the ring or or even a pellet”
-
Dr. Peter Attia, on FoundMyFitness, at 2:53:06 Video · partly · Opinion
“our Preferred Product is an estradiol patch”
-
Dr Sharon Malone, on The Dr. Hyman Show, at 1:02:00 Video · partly · Opinion
“um that a a transermal may be preferable”
-
Cynthia Guyer, on The Dr. Hyman Show, at 18:29 Video · partly · Opinion
“So I tend to use the transdermal because I think it's better tolerated”
-
Gayatri Devi, on The Drive, at 1:49:43 Video · partly · Opinion
“I actually prefer transermal in a you know either a gel or a patch”
-
Other primary study, Int J Cancer, 2005, PMID 15551359 Study · partly
The risk was significantly greater (p <0.001) with HRT containing synthetic progestins than with HRT containing micronized progesterone, the RRs being 1.4 [1.2-1.7] and 0.9 [0.7-1.2], respectively.
-
Trial or observed group, Circulation, 2007, PMID 17309934 Study · partly
In addition, our data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect to thrombotic risk.
-
Other primary study, Breast Cancer Res Treat, 2008, PMID 17333341 Study · partly
This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous).
-
Trial or observed group, BMJ, 2010, PMID 20525678 Study · partly
The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)).
-
Trial or observed group, Menopause, 2014, PMID 24045672 Study · partly
In direct comparisons, various HT doses and regimens are associated with similar rates of cardiovascular events and all-cause mortality.
-
Other primary study, Maturitas, 2006, PMID 16040209 Study · negative
No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p>0.44).
-
Trial or observed group, Am J Epidemiol, 2014, PMID 25008104 Study · negative
In conclusion, micronized progesterone and, to a lesser extent, dydrogesterone at the doses used in France may not be sufficient to prevent estrogen-induced endometrial cancers.
-
Other primary study, Menopause, 2021, PMID 34313612 Study · negative
Among women veterans, the risk of VTE was similar in users of oral CEE, oral E2, and transdermal E2.
-
Other primary study, BJOG, 2024, PMID 38465460 Study · negative
After adjusting for confounding factors, an increased risk of CVD was observed with the administration of tibolone (hazard ratio, HR 1.143, 95% CI 1.117-1.170), oral estrogen (HR 1.246, 95% CI 1.198-1.295) or transdermal estrogen (HR 1.289, 95% CI 1.066-1.558), compared with the non-MHT group; the risk was based on an increased risk of stroke.
-
Other primary study, BMJ, 1997, PMID 9081000 Study · negative
No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations.